ArticleBreast cancer research and treatment2026

EVERolimus effectiveness after proGREssion on ENdocrine therapy plus CDK4/6 inhibitor for ER-positive/HER2-negative advanced breast cancer: EVERGREEN study.

Diogo Martins-Branco et al.PubMed ↗Publisher ↗

No numbers read from the abstract.